Trials / Completed
CompletedNCT01739309
Study of LY2835219 for Mantle Cell Lymphoma
Phase 2 Study of a CDK4/6 Inhibitor for Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to estimate the disease control rate with abemaciclib for relapsed or refractory mantle cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abemaciclib | Administered orally |
Timeline
- Start date
- 2013-03-20
- Primary completion
- 2015-09-28
- Completion
- 2022-09-05
- First posted
- 2012-12-03
- Last updated
- 2023-09-21
- Results posted
- 2019-02-15
Locations
7 sites across 2 countries: France, Germany
Source: ClinicalTrials.gov record NCT01739309. Inclusion in this directory is not an endorsement.